TOP＞R&D / Production
JCR's mission as a biopharmaceutical company has been to engage in the R&D of therapeutic drugs for lysosomal storage diseases, a group of rare genetic diseases. Although drugs already exist for some of the many lysosomal storage diseases, they have not led to improvement in quality of life in practice, due to their limited efficacy and the significant side effects. In order to meet the demand for new treatment options by many patients and their families as soon as possible, we continue with our efforts in our R&D of new, high value-added biotherapeutics utilizing our vast repository of proprietary technologies and know-how.
JCR has incorporated technologies that are one step ahead not only in R&D but also in production. In general, large-capacity bioreactors are required in the culturing process to manufacture biopharmaceuticals. However, although such bioreactors are efficient for large-scale production of a specific product, they are not suited for small-scale production of several products (e.g. orphan drugs) since they need to be washed with large amounts of distilled water after each culture batch. With the knowledge that we would start production of the orphan drugs currently being developed at JCR, we proceeded to construct an efficient system suitable for our needs by making use of the latest technologies such as the adaptation of bioreactors using disposable bags.
We will continue to make efforts to improve our technologies and gather information to provide a stable supply of high-quality, highly useful pharmaceuticals not only in Japan but also the world, and lead the Japanese biopharmaceutical industry now and in the future.